Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5175-5180

  Lakhani, Sunil R ^a,b   Reis Filho, Jorge S ^a   Fulford, Laura ^a   Renault Llorca, Frederique ^d   Van Vijver, Marc Der ^e   Parry, Suzanne ^a   Bishop, Timothy ^f   Benitez, Javier ^g   Rivas, Carmen ^h   Bignon, Yves Jean ^d   Chang Claude, Jenny ⁱ   Hamann, Ute ⁱ   Cornelisse, Cees J ^j   Devilee, Peter ^j   Beckmann, Matthias W ^k   Nestle Krämling, Carolin ^k   Daly, Peter A ^l   Haites, Neva ^m   Varley, Jenny ⁿ   Lalloo, Fiona ^o   Evans, Gareth ^o   Maugard, Christine ^p   Meijers Heijboer, Hanne ^q   Klijn, Jan G M ^q   Olah, Edith ^r   Gusterson, Barry A ^s   Pilotti, Silvana ^t   Radice, Paolo ^t   Scherneck, Siegfried ^u   Sobol, Hagay ^v   Jacquemier, Jocelyne ^v   Wagner, Teresa ^w   Peto, Julian ^a,x   Stratton, Michael R ^a   McGuffog, Lesley ^c   Easton, Douglas F ^c   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d CENTRE JEAN PERRIN   (France)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g Centro Nacional de Investigaciones Oncológicas   (Spain)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j LEIDEN UNIVERSITY   (Netherlands)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l TRINITY COLLEGE DUBLIN   (Ireland)

^m UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o ST MARY S HOSPITAL   (United Kingdom)

^p NANTES UNIVERSITY HOSPITAL   (France)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^s UNIVERSITY OF GLASGOW   (United Kingdom)

^t Istituto Tumori   (Italy)

^u MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^v INSERM   (France)

^w UNIVERSITY OF VIENNA   (Austria)

^x LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; OSTEONECTIN; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE MUTATION; GERM LINE; HETEROZYGOTE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROGNOSIS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 22344443194     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2424     Document Type: Article

References (28)

1. Lakhani S, Easton D, Stratton MR. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997; 349:1505-10.
2. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
3. Lakhani SR,Van DeVijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310-8.
4. Gusterson BA, Warburton MJ, Mitchell D, et al. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res 1982;42:4763-70.
5. Dairkee SH, Ljung BM, Smith H, et al. Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 1987;10:11-20.
6. Heatley M, Maxwell P, Whiteside C, et al. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 1995;48:26-32.
7. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001;85:422-7.
8. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
9. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
10. Tsuda H, Takarabe T, Hasegawa T, et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999;30:1134-9.
11. Tsuda H, Takarabe T, Hasegawa F, et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202.
12. Jimenez RE, Wallis T, Visscher DW. Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior. Am J Surg Pathol 2001;25:331-7.
13. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
14. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003 100:8418-23.
15. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6:782-9.
16. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
17. Santini D, Ceccarelli C, Tardio ML, et al. Immunocytochemical expression of epidermal growth factor receptor in myoepithelial cells of the breast. Appl Immunohistochem Mol Morphol 2002;10:29-33.
18. Jones C, Mackay A, Grigoriadis A, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Can Res 2004;64: 3037-45.
19. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 2003;36:73-84.
20. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482-5.
21. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91:943-91.
22. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
23. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000;18:4053-9.
24. Foulkes WD, Chappuis PO, Wong N, et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000;11:307-13.
25. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-17.
26. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8.
27. Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Can Res 2004;10:5988-97.
28. Cortes-Funes H, Soto Parra H. Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer 2003;89:S3-8.